B. Riley Wealth Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

B. Riley Wealth Management’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q3	–	Sell	-1,050	Closed	-$143K	–	209
2015 Q2	$143K	Buy	1,050 +750	+250%	+$92.9K	0.11%	223
2015 Q1	$37K	Hold	300	–	–	0.03%	469
2014 Q4	$27K	Hold	300	–	–	0.02%	509
2014 Q3	$21K	Sell	300 -400	-57%	-$26.3K	0.02%	590
2014 Q2	$43K	Hold	700	–	–	0.03%	494
2014 Q1	$48K	Buy	+700	New	+$51.6K	0.04%	448

Other funds holding BMRN

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

B. Riley Wealth Management's BMRN Position: Q3 2015 in Review

B. Riley Wealth Management sold out of BioMarin Pharmaceuticals (BMRN) in Q3 2015, closing a stake of 1,050 shares — an estimated $143K sold.

B. Riley Wealth Management first reported a position in BMRN in Q1 2014 and held it in 6 quarters. The position peaked at $143K in Q2 2015. 393 funds tracked by Wall St. Rank hold BMRN as of Q3 2015.

B. Riley Wealth Management reported no remaining BioMarin Pharmaceuticals position as of Q3 2015 after selling out during the quarter.
B. Riley Wealth Management sold 1,050 BioMarin Pharmaceuticals shares in Q3 2015, an estimated $143K.
B. Riley Wealth Management first reported a position in BioMarin Pharmaceuticals in Q1 2014 and held it in 6 quarters.
B. Riley Wealth Management's BioMarin Pharmaceuticals position peaked at $143K in Q2 2015.
393 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q3 2015.

Based on B. Riley Wealth Management's 13F filing for Q3 2015, filed 13 Oct 2015.